TY  - CHAP
M1  - Book, Section
TI  - Diagnosis and Treatment of Rhabdomyosarcoma
A1  - Williams, Felicia N.
A1  - Rodeberg, David A.
A2  - Ziegler, Moritz M.
A2  - Azizkhan, Richard G.
A2  - Allmen, Daniel von
A2  - Weber, Thomas R.
PY  - 2014
T2  - Operative Pediatric Surgery, 2e
AB  - Overall  5-year  survival  for  rhabdomyosarcoma  has  increased  from  25%  to  70%  over  the  past  50  years.Embryonal  rhabdomyosacrcoma  (ERMS)  occurs  in  younger  children  and  has  a  more  favorable  survival  rate  of  60%.In  patients  with  alveolar  tumors  (ARMS),  the  presence  of  regional  nodes  disease  indicates  a  significantly  worse  prognosis,  similar  to  metastatic  disease,  whereas  in  ERMS  tumors  the  outcomes  for  patients  with  regional  node  disease  is  not  any  different  than  localized  disease.All  patients  with  RMS  receive  some  form  of  chemotherapy.  Standard  therapeutic  regimens  consist  of  a  combination  of  vincristine,  actinomycin-D,  and  cyclophosphamide  (VAC).Radiotherapy  (RT)  is  an  important  adjunct  to  therapy  for  many  children  diagnosed  with  RMS,  offering  improved  local  control  and  outcomes.A  more  aggressive  surgical  approach  may  be  warranted  for  recurrent  RMS  and  debulking  is  indicated  in  retroperitoneal  tumors.  
SN  - 
PB  - McGraw-Hill Education
CY  - New York, NY
Y2  - 2024/04/18
UR  - accesspediatrics.mhmedical.com/content.aspx?aid=1100439380
ER  -